iarjmcrIARJMCRIARJMCR2709-3220https://doi.org/10.47310/iarjmcr.2021.v02i01.022Emerging Challenge of Mucormycosis in postCOVID PatientsSuwarnaPatilDilipSarateShriramChopadeManjiriKhadeShwetaDhageSwaradaKangateAs the human-to-human transmitted disease, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been an emergency global public health event. Mucormycosis (previously called zygomycosis) is a serious, sporadic but cosmopolitan, rare opportunistic fungal infection caused by a group of molds called mucormycetes. These molds live throughout the environment. Mucormycosis mainly affects people with serious underlying diseases such as diabetic acidosis and acute leukemia and in patients treated with corticosteroids or cytotoxic drugs7. It most commonly affects the sinuses or the lungs after inhaling fungal spores from the air. Mucormycosis is a rare infection, which when detected early can be controlled. Histopathological confirmation and fungal culture are of significant use in diagnosis of the infections.